| Theme | Evolution in Management of Renal Anemia | |
|---|---|---|
| Title | NESP (novel erythropoiesis stimulating protein) | |
| Publish Date | 2008/01 | |
| Author | Masayuki Iyoda | Department of Nephrology, Showa University School of Medicine |
| Author | Mari Nakamura | Department of Nephrology, Showa University School of Medicine |
| Author | Tadao Akizawa | Department of Nephrology, Showa University School of Medicine |
| [ Summary ] | The 1990 introduction of recombinant human erythropoietin (rHuEPO) in Japan transformed the management of renal anemia. However, the necessity of frequent rHuEPO injections has been an obstacle in providing optimal anemia management for chronic kidney disease (CKD) patients. NESP (novel erythropoiesis stimulating protein ; darbepoetin alfa) was designed to have a prolonged duration of activity, allowing extended dosing intervals relative to rHuEPO. Parmacokinetic studies have confirmed approximately a three-fold longer serum half-life for NESP compared to rHuEPO. In a number of clinical studies, the safety and efficacy of NESP have been demonstrated at a reduced dosing frequency relative to rHuEPO. NESP is likely to simplify anemia management in CKD treatment and offers several clinical advantages for patients and health care providers. | |